Literature DB >> 33443614

[Viral hepatitis A-E].

Annegrit Decker1, Christoph Neumann-Haefelin1, Robert Thimme2.   

Abstract

Hepatitis viruses A-E cause acute and chronic liver inflammation and thus lead to significant morbidity and mortality worldwide. They differ significantly in their biology, course of disease and therapy options. While hepatitis A virus only causes acute infection, hepatitis B can become chronic, even reactivate or occur as coinfection with hepatitis D virus. Whereas these infections are preventable through vaccination, a vaccine does not exist against HCV. However, new direct antiviral agents reliably lead to cure of chronic hepatitis C. Hepatitis E virus frequently causes acute or-in case of immunosuppression-even chronic hepatitis. Continual screening of patients with elevated liver enzymes or risk groups using simple serological markers can enable virus-specific therapy of mostly asymptomatic chronic virus hepatitis, preventing the development of liver cirrhosis and hepatocellular carcinoma.

Entities:  

Keywords:  Antiviral agents, direct acting; HBV reactivation; Hepatitis, acute; Hepatitis, chronic; Liver cirrhosis

Year:  2021        PMID: 33443614     DOI: 10.1007/s00108-020-00923-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  26 in total

Review 1.  Hepatitis A virus seroprevalence by age and world region, 1990 and 2005.

Authors:  Kathryn H Jacobsen; Steven T Wiersma
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

Review 2.  Global Elimination of Chronic Hepatitis.

Authors:  David L Thomas
Journal:  N Engl J Med       Date:  2019-05-23       Impact factor: 91.245

3.  Reply to: "Revisiting the estimation of hepatitis D global prevalence".

Authors:  Alexander J Stockdale; Yvan Hutin; Anna Maria Geretti
Journal:  J Hepatol       Date:  2020-08-27       Impact factor: 25.083

Review 4.  Hepatitis E: Epidemiology, Clinical Course, Prevention, and Treatment.

Authors:  Amit Goel; Rakesh Aggarwal
Journal:  Gastroenterol Clin North Am       Date:  2020-06       Impact factor: 3.806

Review 5.  Hepatitis A.

Authors:  N M Kemmer; E P Miskovsky
Journal:  Infect Dis Clin North Am       Date:  2000-09       Impact factor: 5.982

Review 6.  [Viral Hepatitis: When to be Considered in Clinical Routine?]

Authors:  Hendrik Luxenburger; Robert Thimme; Christoph Neumann-Haefelin
Journal:  Dtsch Med Wochenschr       Date:  2019-04-15       Impact factor: 0.628

7.  Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.

Authors:  Katja Deterding; Christoph D Spinner; Eckart Schott; Tania M Welzel; Guido Gerken; Hartwig Klinker; Ulrich Spengler; Johannes Wiegand; Julian Schulze Zur Wiesch; Anita Pathil; Markus Cornberg; Andreas Umgelter; Caroline Zöllner; Stefan Zeuzem; Armin Papkalla; Kristina Weber; Svenja Hardtke; Heiko von der Leyen; Armin Koch; Dorothee von Witzendorff; Michael P Manns; Heiner Wedemeyer
Journal:  Lancet Infect Dis       Date:  2016-10-28       Impact factor: 25.071

8.  HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients.

Authors:  Dirk Westhölter; Jens Hiller; Ulrike Denzer; Susanne Polywka; Francis Ayuk; Meike Rybczynski; Thomas Horvatits; Svantje Gundlach; Johanna Blöcker; Julian Schulze Zur Wiesch; Nicole Fischer; Marylyn M Addo; Sven Peine; Burkhard Göke; Ansgar W Lohse; Marc Lütgehetmann; Sven Pischke
Journal:  J Hepatol       Date:  2018-03-15       Impact factor: 25.083

9.  Hepatitis E virus and chronic hepatitis in organ-transplant recipients.

Authors:  Nassim Kamar; Janick Selves; Jean-Michel Mansuy; Leila Ouezzani; Jean-Marie Péron; Joëlle Guitard; Olivier Cointault; Laure Esposito; Florence Abravanel; Marie Danjoux; Dominique Durand; Jean-Pierre Vinel; Jacques Izopet; Lionel Rostaing
Journal:  N Engl J Med       Date:  2008-02-21       Impact factor: 91.245

10.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.

Authors:  Jeffrey D Stanaway; Abraham D Flaxman; Mohsen Naghavi; Christina Fitzmaurice; Theo Vos; Ibrahim Abubakar; Laith J Abu-Raddad; Reza Assadi; Neeraj Bhala; Benjamin Cowie; Mohammad H Forouzanfour; Justina Groeger; Khayriyyah Mohd Hanafiah; Kathryn H Jacobsen; Spencer L James; Jennifer MacLachlan; Reza Malekzadeh; Natasha K Martin; Ali A Mokdad; Ali H Mokdad; Christopher J L Murray; Dietrich Plass; Saleem Rana; David B Rein; Jan Hendrik Richardus; Juan Sanabria; Mete Saylan; Saeid Shahraz; Samuel So; Vasiliy V Vlassov; Elisabete Weiderpass; Steven T Wiersma; Mustafa Younis; Chuanhua Yu; Maysaa El Sayed Zaki; Graham S Cooke
Journal:  Lancet       Date:  2016-07-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.